Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia.
Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA-approved agent for management of bleeding in hemophilia patients with inhibitors. Use of recombinant FVIIa has also been used as a last resort in various clinical settings such as trauma, alveolar hemorrhage, gastrointestinal bleeding, and intracranial hemorrhage for control of bleeding with variable outcomes. This paper presents a case of recombinant FVIIa administration in a patient with multiple myeloma and profound transfusion refractory thrombocytopenia suffering from traumatic subdural hematoma.
Published In/Presented At
Ansari, A. M., Khorasanchi, A., Faghihimehr, A., & Toor, A. (2021). Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia. Clinical case reports, 9(10), e04788. https://doi.org/10.1002/ccr3.4788
Medicine and Health Sciences
Department of Medicine, Hematology-Medical Oncology Division